N@N

CABL, BDCO, MDGN, THTCF, Removed From Naked Short Lists Today

^{Published on 2011-06-03 06:11:13 - WOPRAI}
 

June 3, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , announced today that these select companies have been After the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. CHINA CABLECOM HOLDINGS LTD (NASDAQ:CABL), BLUE DOLPHIN ENERGY CO (NASDAQ:BDCO), MEDGENICS INC - UNRESTRICTED (OTCBB:MDGN), THERATECHNOLOGIES INC (OTC:THTCF). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .

CHINA CABLECOM HOLDINGS LTD (NASDAQ:CABL) - China Cablecom Holdings, Ltd. operates as a joint venture provider of cable television services in the People's Republic of China (PRC). It operates in partnership with a local state-owned enterprise (SOE) authorized by the PRC government to control the distribution of cable television services through the deployment of analog and digital cable services. The company has consummated the acquisition of a 55% economic interest in a cable network in Hubei province with paying subscribers of approximately 1,200,000. China Cablecom also acquired operating rights of the Binzhou Broadcasting network in Binzhou, Shandong Province in September 2007 by entering into a series of asset purchase and services agreements with a company organized by SOEs owned directly or indirectly by local branches of state administration of radio, film, and television in five different municipalities to serve as a holding company of the relevant businesses. It operates 28 cable networks with approximately 1.7 million paying subscribers. The company was founded in 2006 and is based in Shanghai, the Peoples Republic of China.There is a failure to deliver in shares of CABL

BLUE DOLPHIN ENERGY CO (NASDAQ:BDCO) - Blue Dolphin Energy Company, through its subsidiaries, engages in the provision of pipeline transportation and related services for producers/shippers, and exploration and production of oil and gas in the United States. Its pipeline transportation and related services include the operation of the Blue Dolphin Pipeline system, which comprise the offshore segment that transports gas and condensate, and consists of approximately 34 miles of 20-inch pipeline from a offshore platform in Galveston Area Block 288 to shore, as well as the platform in Galveston Area Block 288 and 5 field gathering lines totaling approximately 27 miles connected to the main 20-inch line; and the onshore segment consisting of approximately 2 miles of 16-inch pipeline for the transportation of gas from onshore facility to a sales point at a chemical plant complex and intrastate pipeline system tie-in in Freeport, Texas. The companys pipeline systems also include the Buccaneer Pipeline, an 8-inch liquids pipeline, which transports condensate from the onshore facility storage tanks to the company's barge-loading terminal on the Intracoastal Waterway near Freeport, Texas for sale to third parties; and the Galveston Area Block 350 Pipeline consisting of 8-inch, 13 mile offshore pipeline extending from Galveston Area Block 350 to an interconnect with a transmission pipeline in Galveston Area Block 391. In addition, it holds interests in oil and gas properties located in the western Gulf of Mexico off the Texas coast. The company was founded in 1986 and is based in Houston, Texas.There is a failure to deliver in shares of BDCO

MEDGENICS INC - UNRESTRICTED (OTCBB:MDGN) - Medgenics, Inc., a biopharmaceutical company, through its subsidiary Medgenics Medical Israel Ltd., engages in the research and development of products in the field of biotechnology and associated medical equipment. Its Biopump platform technology allows patients to produce their natural human protein therapy for the treatment of a range of chronic diseases, such as anemia and hepatitis C. The company develops EPODURE, a Phase I/II clinical trial product for the treatment of chronic renal anemia; and INFRADURE for the treatment of hepatitis C. It also develops a pipeline of products based on its Biopump technology, such as clotting Factor VIII for the treatment of hemophilia. The companys platform technology also has the potential to treat a range of other therapeutic areas, such as multiple sclerosis, pediatric growth hormone deficiency/muscular atrophy, diabetes, arthritis, wound healing, obesity, chronic pain, and cancer recovery. Medgenics, Inc. was founded in 2000 and is based in Vienna, Virginia.There is a failure to deliver in shares of MDGN

THERATECHNOLOGIES INC (OTC:THTCF) - Theratechnologies Inc., a biopharmaceutical company, engages in the discovery of therapeutic products for commercialization. The companys proprietary technologies include Long Acting Peptides, a peptide stabilization technology that increases the target proteins resistance to enzymatic degradation. Its lead product is tesamorelin, which completed its phase III clinical trial for the treatment of HIV-associated lipodystrophy and is in phase II clinical trials for the treatment of mild cognitive impairment and growth hormone deficient abdominal obesity. The company also develops Acute kidney injury, a preclinical stage product. It has a license agreement with PDC Biotech GmbH to use the antagonists of the prostaglandin F2a receptor in pre-term labor and primary dysmenorrheal; and OctoPlus N.V. to develop and commercialize GLP-1 portfolio of analogues. The company also has a collaboration and licensing agreement with EMD Serono, Inc. for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. The company was founded in 1993 and is headquartered in Montreal, Canada.There is a failure to deliver in shares of THTCF

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 2,750,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.

BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.

BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.

Contact: Thomas Ronk / CEO www.BUYINS.net (800) 715-9999 tom@buyins.net